We had recently shown that loss of the RNA-binding protein tristetraprolin (TTP), a key suppressor of inflammation, promotes tumor plasticity and resistance to enzalutamide in a mouse model of prostate adenocarcinoma (38). Here, ZFP36 is linked to prostate adenocarcinoma.